Disclaimer: Due to limited expertise, errors are inevitable, and some information may not be the most up-to-date. Feel free to point out in the comments. This article is only an introduction to medical and health-related drugs, not a recommendation of treatment options (if involved); it does not constitute any investment advice.
Recently, Shanghai Grail Bio Co., Ltd. (Grail Bio) and Shandong Quangang Pharmaceutical Co., Ltd. (Quangang Pharma) announced the official establishment of a strategic partnership to fully leverage their respective capabilities in innovative cell drug research and development. The aim is to jointly develop TIL cell therapy technology combined with recombinant human interleukin-2 (I) (brand name: Quanqi) for the treatment of solid tumors, supporting the development and subsequent clinical use of T-cell therapies. The signing of this agreement marks a powerful collaboration between the two parties in the biotechnology field, promising more effective and accessible treatment options for patients with solid tumors.
It is reported that the focus of cooperative development will be on the expansion of solid tumor indications for the product Quanqi. As a domestically marketed interleukin-2 (I) product in China, Quanqi is mainly used for the treatment of malignant tumors such as renal cell carcinoma, melanoma, breast cancer, bladder cancer, liver cancer, rectal cancer, lymphoma, and lung cancer. It is an important immune-modulating cytokine in T-cell therapy, and its efficacy and safety play a crucial role in the effectiveness of cell therapy. Through this collaboration, both parties will work together to develop the clinical efficacy of combining TIL cell therapy technology with Quanqi for the treatment of solid tumors, as well as to develop a suitable human interleukin-2 (Ⅰ) specification for TIL cell therapy. This effort aims to provide stronger support for T-cell therapy to meet the needs of Chinese patients with solid tumors for high-quality and highly effective treatments.Grail Bio's TIL Cell Therapy Technology is an innovative immunotherapy that utilizes patients' own tumor-infiltrating lymphocytes (TIL) for treatment, offering a new therapeutic option for solid tumor patients. Shandong Quangang Pharmaceutical Co., Ltd., a leading Chinese biopharmaceutical company specializing in the research, production, and sales of biologics, has extensive technical expertise and experience in the development of recombinant protein drugs and enjoys a strong reputation and influence in the biopharmaceutical industry. Through collaboration with Shandong Quangang Pharmaceutical, Grail Bio will leverage its experience in cell therapy product development and commercialization to accelerate the progress and market entry of cell therapy products, bringing new options and hope to more solid tumor patients.Both parties expressed that the establishment of this strategic partnership not only marks a solid step forward in the collaboration between Grit Biotechnology and Shandong Quangang Pharmaceutical Co., Ltd. in the biopharmaceutical field, but will also further accelerate the research and development process of TIL cell therapy combined with human interleukin-2 (Ⅰ) for the treatment of solid tumors. This will make a positive contribution to the advancement of China’s cell therapy industry. It is believed that with the joint efforts of both parties, in the near future, Chinese patients with solid tumors will have access to more advanced and effective biological treatment options, bringing new hope to the treatment of severe diseases such as cancer.Source of the article: Grail Bio
